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While regulatory agencies require stringent product quality and safety to be upheld in biopharmaceutical
products, today’s competitive biopharmaceutical market requires short process development times. The demand
to accelerate especially the development of vaccines became obvious with the COVID-19 pandemic. By
expanding process understanding with the use of process design tools the development time of the purification
could be significantly shortened.
High throughput experimentation (HTE) provides an automated experimentation platform, which minimizes the
amount of used samples and saves experimental time. In this approach, HTE is used to acquire experimental
data to regress parameters used as inputs for a chromatographic mechanistic model with the objective to
establish an E. coli vaccine purification process development platform for a recombinant subunit vaccine. To
provide a generic process development strategy that can be applied to novel antigens, the focus lies on the
description of the adsorption behavior of the impurities such as host cell proteins (HCPs) during the capture
step. Therefore our approach focuses on the present impurities, in specific the HCPs (Figure 1). When using the
same E.coli strain the knowledge regarding the host cell proteins could be transferred to a new product. The first
step is the identification of HCPs. Over a thousand HCPs are identified in the E.coli harvest sample investigated
by means of mass spectrometry based proteomics. A database containing the properties of these proteins can
provide assistance in the decision on chromatography resins suited for the purification process of a new
developed antigen.

Figure 1 – Development of purification process for new antigen
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